Core Insights - The company, Kangzheng Pharmaceutical, has signed a distribution agreement with Novartis Pharma Services AG for the exclusive import, distribution, sales, and promotion rights of two ophthalmic products in mainland China [1][2] - The collaboration is expected to enhance the competitiveness of Kangzheng Weisheng in the ophthalmology sector, which already covers various eye diseases [2] Group 1 - The agreement grants Kangzheng exclusive rights for the products Ranibizumab Injection (trade name: 诺适得) and Brolucizumab Injection (trade name: 倍优适) for a period of five years [1] - Novartis will continue to be responsible for the production and supply of these products [1] - Novartis is a globally recognized pharmaceutical company focusing on four core therapeutic areas and five key technology platforms [1] Group 2 - The addition of these products is expected to create synergies with existing offerings, enhancing academic brand competitiveness in the ophthalmology field [2] - Kangzheng Weisheng's professional ophthalmology team will integrate market channels and academic resources to improve overall team efficiency [2] - The anticipated outcome of this collaboration is a positive impact on the company's performance and a broader range of treatment options for patients with eye diseases [2]
康哲药业(00867)与诺华签订眼科药物诺适得与倍优适经销协议